Recruiting

Observational Study

Sponsor:

National Center for Research Resources (NCRR)

Code:

NCT00008749

Conditions

Lupus Erythematosus, Systemic

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Conditions

Lupus Erythematosus, Systemic

Study ID

NCT00008749

Status verified date

Dec, 2003

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Inclusion:

A diagnosis of systemic lupus erythematosus

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

Central contacts

Randy Q Cron, MD, Ph.D.

215-590-1844

Locations

Children's Hospital of Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19104-4318

Contacts

Randy Q Cron, M.D., Ph.D.

215-590-1844

More Information

Sponsor

National Center for Research Resources (NCRR)

Last update posted

Jun 24, 2005

Last verified

Dec, 2003

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by National Center for Research Resources (NCRR) on 2005-06-24.